Skip to main content
Third-party tested
Purity documentation available
Research supply chain
Compliance notice included
GLP-3Reta
99%+ Purity

GLP-3Reta

GLP-3R is a 39 amino acid synthetic peptide engineered to activate three different receptors involved in metabolism: the GIP receptor, the GLP-1 receptor, and the glucagon receptor. That triple-receptor approach sets it apart from peptides that target just one or two of those systems. Researchers use it to explore what happens when all three pathways are switched on together, particularly in models studying energy balance, nutrient processing, and liver fat content. For Research Use Only. Not intended for human or veterinary use.

1
$69.99
We accept

Certificate of Analysis

Third Party TestedISO/IEC 17025 Accredited
ISO 170253rd Party
99.12%
Purity
Passed full QC panel
Lot #RETA-20MG-BA-239
TestedAug 15, 2026
Full QC Panel
Purity (HPLC)99.12%
Net Peptide Content20.57mg
Identity (HPLC)Confirmed
Heavy Metals (ICP-MS)Not Detected
Sterility (PCR)No Growth
Endotoxin (USP <85>)NMT 0.05 EU/mL
ISO/IEC 17025 Accredited
ISO 170253rd Party
99.735%
Purity
Passed full QC panel
TestedJan 26, 2026
Full QC Panel
Purity (HPLC)99.735%
ISO/IEC 17025 Accredited
ISO 170253rd Party
20.57mg
Net Peptide Content
Lot #RETA-20MG-BA-239
TestedAug 15, 2026
ISO/IEC 17025 Accredited
ISO 170253rd Party
Pass
Endotoxin
Lot #RETA-20MG-BA-239
TestedAug 15, 2026
Full QC Panel
Endotoxin (USP <85>)NMT 0.05 EU/mL
ISO/IEC 17025 Accredited
ISO 170253rd Party
Pass
Heavy Metals
Lot #RETA-20MG-BA-239
TestedAug 15, 2026
Full QC Panel
Heavy Metals (ICP-MS)Not Detected
ISO/IEC 17025 Accredited
ISO 170253rd Party
Pass
Identity
Lot #RETA-20MG-BA-239
TestedAug 15, 2026
Full QC Panel
Identity (HPLC)Confirmed
ISO/IEC 17025 Accredited
ISO 170253rd Party
Pass
Microbial & Sterility
Lot #RETA-20MG-BA-239
TestedAug 15, 2026
Full QC Panel
Sterility (PCR)No Growth
ISO/IEC 17025 Accredited
ISO 170253rd Party
Pass
Fentanyl Screen
Lot #RETA-20MG-BA-239
TestedAug 15, 2026
ISO/IEC 17025 Accredited
ISO 170253rd Party
99.12%
Purity
Passed full QC panel
Lot #RETA-20MG-BA-239
TestedAug 15, 2026
Full QC Panel
Purity (HPLC)99.12%
Net Peptide Content20.57mg
Identity (HPLC)Confirmed
Heavy Metals (ICP-MS)Not Detected
Sterility (PCR)No Growth
Endotoxin (USP <85>)NMT 0.05 EU/mL
ISO/IEC 17025 Accredited
ISO 170253rd Party
99.735%
Purity
Passed full QC panel
TestedJan 26, 2026
Full QC Panel
Purity (HPLC)99.735%
ISO/IEC 17025 Accredited
ISO 170253rd Party
20.57mg
Net Peptide Content
Lot #RETA-20MG-BA-239
TestedAug 15, 2026
ISO/IEC 17025 Accredited
ISO 170253rd Party
Pass
Endotoxin
Lot #RETA-20MG-BA-239
TestedAug 15, 2026
Full QC Panel
Endotoxin (USP <85>)NMT 0.05 EU/mL
ISO/IEC 17025 Accredited
ISO 170253rd Party
Pass
Heavy Metals
Lot #RETA-20MG-BA-239
TestedAug 15, 2026
Full QC Panel
Heavy Metals (ICP-MS)Not Detected
ISO/IEC 17025 Accredited
ISO 170253rd Party
Pass
Identity
Lot #RETA-20MG-BA-239
TestedAug 15, 2026
Full QC Panel
Identity (HPLC)Confirmed
ISO/IEC 17025 Accredited
ISO 170253rd Party
Pass
Microbial & Sterility
Lot #RETA-20MG-BA-239
TestedAug 15, 2026
Full QC Panel
Sterility (PCR)No Growth
ISO/IEC 17025 Accredited
ISO 170253rd Party
Pass
Fentanyl Screen
Lot #RETA-20MG-BA-239
TestedAug 15, 2026
ISO/IEC 17025 Accredited

Compound Information

Structured specifications and handling data

Molecular profile

Technical specifications

Type:Synthetic Peptide (Triple Agonist)
CAS Number:2381089-83-2
Molecular Weight:4731.33 g/mol
Amino Acids:39
Sequence:YA¹QGTFTSDYSIL²LDKK⁴AQA¹AFIEYLLEGGPSSGAPPPS³ (where A¹=Aib, L²=α-methyl-L-leucine, K⁴=lysine with (AEEA)-(γ-Glu)-(C20 diacid) side chain, S³=serinamide; full one-letter sequence with modifications refer to structural diagrams in primary literature)
Formula:C221H342N46O68
PubChem Database
Storage requirements

Stability and handling

Lyophilized
Cold Storage
Storage TemperatureStore in a cool, dry place away from light; refrigerate at 2–8°C (36–46°F)
ReconstitutionReconstitute with sterile water or bacteriostatic water
StabilityStable when stored properly; avoid repeated freeze-thaw cycles
Chemical structure

Molecular model

3D Interactive

Loading 3D Molecule...

Left click to rotate • Scroll to zoom

GLP-3Reta research overview

GLP-3R is designed to hit three receptors that play important roles in how the body processes nutrients. Two of them, GIP and GLP-1, belong to the incretin system, a group of gut hormones that help coordinate insulin release after eating. The third, the glucagon receptor, is involved in how the liver manages stored energy. By activating all three at once, GLP-3R gives researchers a way to study what happens when these overlapping systems are engaged simultaneously.

Like GLP-2T, GLP-3R has been modified with a fatty acid chain that lets it bind to albumin in the bloodstream, keeping it active longer in experimental models. In cell-based studies, researchers have measured how it triggers cyclic AMP production (a key intracellular signal) at each of the three receptor types. The activation profile is not equal across all three, which is itself an area of active research.

Animal studies have explored GLP-3R in models looking at energy expenditure, food intake, and liver fat content. Comparative research has examined how triple-receptor activation differs from dual or single-receptor activation, helping scientists piece together how these metabolic pathways interact with each other. For Research Use Only. Not intended for human or veterinary use.

Multi-Receptor Pharmacology

Has been characterized for binding and activation profiles at GLP-1, GIP, and glucagon receptors in cell assays.

Behavioral Studies

Animal research has investigated associations with feeding behavior and satiety signaling in experimental models.

Metabolic Rate Assays

Research has explored effects on oxygen consumption and energy expenditure in metabolic chamber experiments.

Body Composition Analysis

Studies have examined changes in fat mass, lean mass, and hepatic lipid content in animal models.

Research evidence

Published studies and concise summaries for research review.

Research Paper
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Triple-Hormone-Receptor Agonist GLP-3R for Obesity - A Phase 2 Trial
Jastreboff AM et al.
Research Paper
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

AI-generated summary of this research paper below.

This landmark phase 2, double-blind, randomized, placebo-controlled trial evaluated once-weekly subcutaneous GLP-3R (various doses up to 12 mg) versus placebo in 338 adults with obesity (BMI ≥30 or ≥27 with comorbidities) over 48 weeks. GLP-3R produced dose-dependent, substantial weight loss, with the highest dose (12 mg) achieving a mean reduction of 24.2% (approximately 58 lbs) at 48 weeks and 17.5% at 24 weeks, far exceeding placebo (-1.6% at 24 weeks). Improvements included reductions in waist circumference, blood pressure, lipids, HbA1c, and fasting insulin/glucose, with preserved lean mass proportion. Gastrointestinal adverse events (nausea, vomiting, diarrhea) were common, mostly mild-to-moderate during dose escalation, and heart rate increases were observed but manageable. This trial established GLP-3R's superior efficacy as a triple agonist (GIP/GLP-1/glucagon) compared to dual agents like GLP-2T/GLP-1S, paving the way for phase 3 TRIUMPH program.
Research overview
Total Papers
122+
Year Range
2023+
Research status
Active
Peer-reviewed studies available
Research FAQ

Frequently asked questions

Concise answers about laboratory context, handling, and documentation for this compound.

Laboratory compliance notice

All compounds sold by Validated Peptides are intended for in-vitro laboratory research only.

These materials are not approved by the FDA for human or animal use and are not intended for diagnostic, therapeutic, or clinical applications.

Purchasers are responsible for compliant handling, storage, and use within an appropriate laboratory environment.

Research Use Only
Not for Human Use
21+ Required